BOSTON (FINALLY) — I slept little, ate poorly, drank moderately, and didn’t exercise, save for a single walk up a big hill with Luke Timmerman. I attended meetings, presentations, and breakouts. It rained a lot. I talked to lots of people. I was asked, “How’s your meeting going?” 7,568 times. I wrote some words and tweeted. I lived in a rented house with six STAT co-workers and brewed an insane amount of coffee.
I flew to San Francisco with some burning biotech questions on my mind. Now that the J.P. Morgan Healthcare Conference 2018 is in the books, here are some of the burning answers.
Incyte management failed to boost investor confidence in the imminent outcome of the all-important epacadostat-Keytruda phase 3 clinical trial. In fact, a discussion of biomarker analyses expected to be conducted on melanoma patients in the study — first mentioned during Monday’s breakout session — raised more fears Incyte was planning to spin bad news.
About the Author Reprints
